{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:52:37Z","timestamp":1776664357008,"version":"3.51.2"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2026.1833581","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:23:47Z","timestamp":1776662627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial: Community Series in Engineered Immune Cells in Cancer Immunotherapy (EICCI), volume II"],"prefix":"10.3389","volume":"17","author":[{"given":"Axel","family":"Schambach","sequence":"first","affiliation":[{"name":"Institute of Experimental Hematology, Hannover Medical School","place":["Hannover, Germany"]},{"name":"Division of Hematology\/Oncology, Boston Children\u2019s Hospital, Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Martin","sequence":"additional","affiliation":[{"name":"GENYO, Centre for Genomics and Oncological Research, Pfizer, University of Granada, Andalusian Regional Government, Parque Tecnol\u00f3gico Salud (PTS) Granada","place":["Granada, Spain"]},{"name":"Instituto de Investigaci\u00f3n Biosanitaria ibs.GRANADA","place":["Granada, Spain"]},{"name":"Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, Excellence Research Unit \u201cModeling Nature\u201d (MNat), University of Granada","place":["Granada, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Maccalli","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliera Metropolitana Plesso Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"9","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T Cells: More than Ease of Access","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.047","article-title":"Comparison of Zinc Finger Nucleases Versus CRISPR-Specific Nucleases for Genome Editing of the Wiskott-Aldrich Syndrome Locus","volume":"29","author":"Gutierrez-Guerrero","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.retram.2018.04.003","article-title":"CRISPR\/Cas9 genome editing: Fueling the revolution in cancer immunotherapy","volume":"66","author":"Liu","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.233882","article-title":"Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing alphabeta T cell-depleted haploidentical hematopoietic stem cell transplantation","volume":"106","author":"Wiebking","year":"2020","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1401683","article-title":"Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR\/Cas9 editing and safety evaluation of the transcriptome","volume":"15","author":"Pavlovic","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1011858","article-title":"Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma","volume":"13","author":"Maldonado-Perez","year":"2022","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1291619","DOI":"10.3389\/fimmu.2022.1012981","article-title":"Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils","volume":"14","author":"Liang","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1202950","DOI":"10.3389\/fimmu.2023.1187665","article-title":"Beyond alphabeta T cells: NK, iNKT, and gammadeltaT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML","volume":"14","author":"Kent","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"969196","DOI":"10.3389\/fimmu.2023.1291619","article-title":"A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1302307","DOI":"10.3389\/fimmu.2022.969196","article-title":"CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer","volume":"14","author":"Nasiri","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1018786","DOI":"10.3389\/fimmu.2023.1302307","article-title":"CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"968395","DOI":"10.3389\/fimmu.2023.1219165","article-title":"CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies","volume":"13","author":"To","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1187665","DOI":"10.3389\/fimmu.2022.1018786","article-title":"NKG2D-CAR memory T cells target pediatric T-cell acute lymphoblastic leukemia in vitro and in vivo but fail to eliminate leukemia initiating cells","volume":"14","author":"Ibanez-Navarro","year":"2023","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fimmu.2023.1202950","article-title":"NKG2D Ligands in Tumor Immunity: Two Sides of a Coin","volume":"6","author":"Zhang","year":"2015","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"713158","DOI":"10.3389\/fimmu.2015.00097","article-title":"Leveraging NKG2D Ligands in Immuno-Oncology","volume":"12","author":"Fuertes","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1219165","DOI":"10.3389\/fimmu.2022.968395","article-title":"CAR-Ts redirected against the Thomsen-Friedenreich antigen CD176 mediate specific elimination of malignant cells from leukemia and solid tumors","volume":"14","author":"Dragon","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1012981","DOI":"10.3389\/fimmu.2021.713158","article-title":"Case report: CD38-directed CAR-T cell therapy: A novel immunotherapy targeting CD38- positive blasts overcomes TKI and chemotherapy resistance of myeloid chronic myeloid leukemia in blastic phase","volume":"13","author":"Cui","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1239132","DOI":"10.3389\/fimmu.2023.1219165","article-title":"Mediport use as an acceptable standard for CAR T cell infusion","volume":"14","author":"Eylon","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.994885","article-title":"Transcriptional states of CAR-T infusion relate to neurotoxicity - lessons from high-resolution single-cell SOM expression portraying","volume":"13","author":"Loeffler-Wirth","year":"2022","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.943004","article-title":"Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed\/refractory multiple myeloma treated with CAR-T therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1833581\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T05:23:47Z","timestamp":1776662627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1833581\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1833581"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1833581","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1833581"}}